Alector, Inc. (NASDAQ:ALEC) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Alector, Inc. has received a consensus rating of "Hold" from seven research firms, with two analysts recommending a sell and four a buy.
• The company's stock price has fluctuated between a 1 year low of $0.87 and a high of $6.37, currently opening at $2.40.
• Alector reported a quarterly earnings of ($0.30) EPS, surpassing expectations and generating revenue of $7.87 million, significantly higher than analysts' predictions.

Alector, Inc. (NASDAQ:ALEC - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $4.1667.

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Alector from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Mizuho raised shares of Alector from a "neutral" rating to an "outperform" rating and lifted their price target for the stock from $2.50 to $3.50 in a research report on Monday, July 28th. Finally, HC Wainwright upped their price objective on shares of Alector from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

Alector Price Performance

Shares of ALEC opened at $2.40 on Thursday. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.13. Alector has a 1 year low of $0.87 and a 1 year high of $6.37. The stock has a market cap of $242.90 million, a P/E ratio of -2.07 and a beta of 0.86. The stock's 50-day moving average price is $1.75 and its two-hundred day moving average price is $1.48.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. The company had revenue of $7.87 million during the quarter, compared to analysts' expectations of $2.76 million. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%. Alector has set its FY 2025 guidance at EPS. On average, equities analysts predict that Alector will post -1.88 earnings per share for the current year.

Insider Activity

In other news, Director Paula Hammond sold 14,000 shares of Alector stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total transaction of $33,040.00. Following the transaction, the director owned 74,909 shares in the company, valued at $176,785.24. The trade was a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Northern Trust Corp increased its position in shares of Alector by 5.6% during the fourth quarter. Northern Trust Corp now owns 759,874 shares of the company's stock worth $1,436,000 after acquiring an additional 40,291 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Alector by 723.0% during the 4th quarter. BNP Paribas Financial Markets now owns 165,589 shares of the company's stock worth $313,000 after purchasing an additional 145,469 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Alector by 26.1% in the 4th quarter. Hsbc Holdings PLC now owns 57,983 shares of the company's stock valued at $109,000 after purchasing an additional 12,004 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Alector by 12.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,570 shares of the company's stock valued at $303,000 after purchasing an additional 17,509 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Alector by 27.7% in the fourth quarter. Invesco Ltd. now owns 47,985 shares of the company's stock valued at $91,000 after purchasing an additional 10,405 shares in the last quarter. Institutional investors own 85.83% of the company's stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.